Swiss National Bank Purchases 2,300 Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY)

Swiss National Bank grew its position in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 2.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 112,900 shares of the biopharmaceutical company’s stock after buying an additional 2,300 shares during the period. Swiss National Bank owned 0.16% of CymaBay Therapeutics worth $808,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA purchased a new position in shares of CymaBay Therapeutics in the 1st quarter valued at approximately $165,000. Spark Investment Management LLC raised its position in shares of CymaBay Therapeutics by 47.9% in the 1st quarter. Spark Investment Management LLC now owns 183,800 shares of the biopharmaceutical company’s stock valued at $2,440,000 after purchasing an additional 59,500 shares during the last quarter. Vivo Capital LLC raised its position in shares of CymaBay Therapeutics by 126.9% in the 1st quarter. Vivo Capital LLC now owns 2,056,000 shares of the biopharmaceutical company’s stock valued at $27,304,000 after purchasing an additional 1,150,000 shares during the last quarter. Marshall Wace LLP raised its position in shares of CymaBay Therapeutics by 17.0% in the 1st quarter. Marshall Wace LLP now owns 63,589 shares of the biopharmaceutical company’s stock valued at $844,000 after purchasing an additional 9,231 shares during the last quarter. Finally, Marshall Wace North America L.P. raised its position in shares of CymaBay Therapeutics by 1,744.6% in the 1st quarter. Marshall Wace North America L.P. now owns 122,792 shares of the biopharmaceutical company’s stock valued at $1,631,000 after purchasing an additional 116,135 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

CBAY traded down $0.03 during trading on Friday, reaching $5.98. 42,740 shares of the company’s stock were exchanged, compared to its average volume of 373,749. CymaBay Therapeutics Inc has a 1 year low of $4.82 and a 1 year high of $14.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 16.20 and a quick ratio of 16.20. The stock has a market capitalization of $412.89 million, a P/E ratio of -4.75 and a beta of 1.26. The company’s fifty day simple moving average is $5.94 and its 200-day simple moving average is $9.67.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. Equities analysts forecast that CymaBay Therapeutics Inc will post -1.47 EPS for the current year.

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective (down from $24.00) on shares of CymaBay Therapeutics in a research report on Wednesday, June 12th. Citigroup decreased their price objective on shares of CymaBay Therapeutics from $21.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, June 13th. Stifel Nicolaus assumed coverage on shares of CymaBay Therapeutics in a research report on Monday, June 24th. They issued a “buy” rating and a $14.00 price objective for the company. BidaskClub lowered shares of CymaBay Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 30th. Finally, Piper Jaffray Companies reduced their price target on shares of CymaBay Therapeutics from $30.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, June 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $14.09.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Featured Story: Momentum Investing

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.